Historique
Rapport
Opioid use disorder. Treatment with injectable and implantable buprenorphine. Report to Congressional Committees
Auteur(s) :
United States Government Accountability Office (GAO)
Année
2020
Page(s) :
21 p.
Langue(s) :
Anglais
Éditeur(s) :
Washington, DC : U.S. Government Accountability Office (GAO)
, GAO-20-617
Domaine :
Autres substances / Other substances ; Drogues illicites / Illicit drugs
Thésaurus géographique
ETATS-UNIS
Thésaurus mots-clés
OPIOIDES
;
TRAITEMENT DE MAINTENANCE
;
BUPRENORPHINE
;
INJECTION
;
VOIE D'ADMINISTRATION
;
VOIE SOUSCUTANEE
;
VOIE INTRAMUSCULAIRE
;
PRESCRIPTION MEDICALE
;
PHARMACIE
Note générale :
Voir aussi :
Rubin R. Buprenorphine implants, injections are underused. Journal of the American Medical Association, 2020, Vol. 324, n° 12, p. 1128. https://doi.org/10.1001/jama.2020.17587
Rubin R. Buprenorphine implants, injections are underused. Journal of the American Medical Association, 2020, Vol. 324, n° 12, p. 1128. https://doi.org/10.1001/jama.2020.17587
Résumé :
Treatment for opioid use disorder may involve buprenorphine - a drug that can reduce or eliminate withdrawal symptoms and prevent relapse.
We reviewed the use of long-acting injectable and implantable forms of buprenorphine for opioid use disorder. These forms release the drug over 1- or 6-month periods respectively.
Providers issued about 7,250 prescriptions for injectable or implantable buprenorphine in FY 2019.
Providers and pharmacy representatives said there is a low risk of these forms of the drug being diverted to the illegal marketplace.
We reviewed the use of long-acting injectable and implantable forms of buprenorphine for opioid use disorder. These forms release the drug over 1- or 6-month periods respectively.
Providers issued about 7,250 prescriptions for injectable or implantable buprenorphine in FY 2019.
Providers and pharmacy representatives said there is a low risk of these forms of the drug being diverted to the illegal marketplace.
Affiliation :
Washington, DC, USA